Standard dosing intervals for BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines are 21 and 28 days, respectively.1 Data suggest improved effectiveness of ChAdOx1 adenoviral2 and other nonreplicating vaccines3 with increased dosing intervals, but little data exist for mRNA vaccines. This study investigated the immunogenicity of extended mRNA vaccine dosing intervals.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Brian Grunau, MD, MHSc, British Columbia Resuscitation Research Collaborative, 1190 Hornby St, Fourth Floor, Vancouver, BC V6Z 2K5, Canada (firstname.lastname@example.org).
Accepted for Publication: November 18, 2021.
Published Online: December 3, 2021. doi:10.1001/jama.2021.21921
Author Contributions: Drs Grunau and Lavoie had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Grunau, Goldfarb, Asamoah-Boaheng, Kirkham, Demers, Lavoie.
Acquisition, analysis, or interpretation of data: Grunau, Asamoah-Boaheng, Golding, Kirkham, Demers, Lavoie.
Drafting of the manuscript: Grunau, Asamoah-Boaheng, Lavoie.
Critical revision of the manuscript for important intellectual content: Goldfarb, Asamoah-Boaheng, Golding, Kirkham, Demers, Lavoie.
Statistical analysis: Asamoah-Boaheng, Lavoie.
Obtained funding: Grunau, Goldfarb, Kirkham, Demers, Lavoie.
Administrative, technical, or material support: Goldfarb, Golding, Kirkham, Demers.
Supervision: Grunau, Goldfarb, Kirkham, Lavoie.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported by funding from the government of Canada, through the COVID-19 Immunity Task Force.
Role of the Funder/Sponsor: The government of Canada had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Mohammad Ehsanul Karim, PhD (School of Population and Public Health, University of British Columba), for providing statistical expertise; Paul N. Levett, PhD, and Martin Petric, PhD (British Columbia Centre for Disease Control), for performing live virus neutralization testing; Richard Armour, MSc (British Columbia Emergency Health Services), for assisting with participant enrollment; and Vilte Barakauskas, PhD (British Columbia Children’s and Women’s Hospital), for managing specimens. No compensation was received for their contributions to this work.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.